Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
Olema Oncology announced a clinical trial collaboration and supply agreement with Bayer to evaluate its KAT6 inhibitor OP-3136 in combination with Bayer’s NUBEQA (darolutamide). The Phase 1b/2 study will assess safety and preliminary anti-tumor activity in approximately 36 patients with metastatic castration-resistant prostate cancer (mCRPC), with initiation expected in the second half of 2026. This marks the first clinical collaboration for OP-3136, expanding its development beyond breast cancer.
Key figures
- Drug Name
- OP-3136
- Phase Of Trial
- Phase 1b/2
- Study start
- H2 2026
- Patient count
- 36
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.